Sodium phosphate monohydrate, monobasic

Per vial 23 mg glycine 1.6 mg SC dibasic sodium phosphate heptahydrate 0.55 mg monobasic sodium phosphate monohydrate... 

To be reconstituted with sterile WFI (pH approximately 7.2) Per lOmL 500 mg sucrose 0.5 mg polysorbate 80 2.2 mg monobasic sodium phosphate monohydrate 6.1 mg dibasic sodium phosphate dihydrate IV infusion... 

Anhydrous monobasic sodium phosphate [7558-80-7] Monobasic sodium phosphate monohydrate [10049-21-5] Monobasic sodium phosphate dihydrate [13472-35-0]... 

One gram of monobasic sodium phosphate monohydrate represents approximately 7.2 mmol of sodium and of phosphate. 

For subcutaneous injection after reconstitution with either SWFi, LISP for single-dose ampules or BWFI (0.9% benzyl alcohol), LISP for multiple-dose vials. Each ampule contains either 37.5, 75, or 150 lU rFSH, 30 mg of sucrose, 1.11 mg of dibasic sodium phosphate, and 0.45 mg of monobasic sodium phosphate monohydrate. 0-phosphoric acid and/or sodium hydroxide may be used prior to iyophiiization for pH adjustment, it may contain up to 15% of oxidized FSH. 

M NaCl. To 900 mL of deionized water, add 0.53 g of monobasic sodium phosphate monohydrate (NaH2P04-H20) and 0.87 g of dibasic sodium phosphate anhydrous (Na2HP04). Add 8.77 g of sodium chloride (NaCl) and dilute to a final volume of 1,000 mL with deionized water. 

In addition, each package consisting of five labeling units contains also five vials of methylene blue injection 1% USP (10 mg methylene blue USP in 1 ml water for injection), and five vials containing 0.003 M monobasic sodium phosphate USP and dibasic sodium phosphate USP in 4.5 ml of 0.9% sodium chloride injection USP. Each milliliter contains 0.276 mg monobasic sodium phosphate monohydrate, 0.142 mg dibasic sodium phosphate anhydrous, and 9 mg sodium chloride in water for injection for a sufficient amount. A mixture of methylene blue in phosphate buffer is used for stabilization of the Tc-HMPAO complex (Amersham Healthcare 1995). 

Fleat 75% of the water to 70°C in a suitable vessel. Add the monobasic sodium phosphate monohydrate, anhydrous dibasic sodium phosphate, propylene glycol, and benzyl alcohol to the vessel with agitation, maintaining the temperature at 70°C. 

There have been several studies of weekly administration of exenatide, using a formulation of exenatide microspheres with poly (D,L-lactide-co-glycolide), which is available as a powder for dissolution in a solvent that includes carmellose sodium, sodium chloride, polysorbate 20, monobasic sodium phosphate monohydrate, and dibasic sodium phosphate heptahydrate. The 2-mg dose of exenatide once in suspension should be injected immediately [49 ]. 

Each syringe deiivers 0.8 ml (40 mg) of DP. Each vial contains approximately 0.9 mL of solution to deiiver 0.8 ml (40 mg) of DP. Each 0.8 ml contains 40 mg of adaiimumab, 4.93 mg of sodium chioride, 0.69 mg of monobasic sodium phosphate dihydrate, 1.22 mg of dibasic sodium phosphate dihydrate, 0.24 mg of sodium citrate, 1.04 mg of citric acid monohydrate, 9.6 mg of mannitol, 0.8 mg of polysorbate 80 and water for injection, USP. Sodium hydroxide added as necessary to adjust pH. 

Mono (2-aminoethyl) sulfate. See Amlnoethyl sulfate Monobasic sodium phosphate. See Sodium phosphate Monobutylamine Mono-n-butylamine. See n-Butylamine Monobutyl glycol ether. See Butoxyethanol Mono-t-butyl hydroquinone. See t-Butyl hydroquinone Monocalcium carbonate. See Calcium carbonate Monocalcium dihydrogen diphosphate. See Calcium dihydrogen pyrophosphate Calcium dihydrogen diphosphate Monocalcium orthophosphate monohydrate Monocalcium phosphate monohydrate. See Calcium phosphate monobasic monohydrate Monocaprin. See Glyceryl caprate... 

Avastin Avastin is used for the treatment of colorectal cancer. It is supplied in 100 and 400 mg dosages. The 100 mg formulation consists of 240 mg a,a-trehalose dihydrate, 23.2 mg sodium phosphate (monobasic, monohydrate), 4.8mg sodium phosphate (dibasic, anhydrous), 1.6mg polysorbate 20 and water-for-injection. 

Formulation Aranesp is formulated as a sterile, colorless, preservative-free protein solution for intravenous (IV) or subcutaneous (SC) administration. There are two formulations the polysorbate solution includes excipients such as polysorbate 80, sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous, and sodium chloride in water-for-injection while the albumin solution contains albumin, sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous, and sodium chloride in water-for-injection. The pH for both formulations is 6.2 + 0.2. 

A new formulation of a saline laxative, Visicol, that is useful to prepare patients for procedures, was approved for use in 2001. Each 2-g tablet contains 1.102 g sodium phosphate monobasic monohydrate and 0.398 g sodium phosphate dibasic anhydrous, for a total of 1.5 g sodium phosphate. Visicol tablets, taken in two doses of 30 g approximately 12 hours apart, induce diarrhea that rapidly and effectively cleanses the entire colon. Each administration has a purgative effect for approximately 1 to 3 hours. 

CHO-expressed glycoprotein] Pharmaceuti- (single-dose vial) cals mL (pH = 5.5) 43.9mg sodium chloride 63.5mg sodium phosphate monobasic monohydrate 10.7 mg sodium phosphate dibasic heptahydrate 0.05 mg polysorbate 80 0.9% NaCl containing 1% HSA prior to administration)... 

Per 1 mL 2.5 mg albumin (human) 1.2 mg sodium phosphate monobasic monohydrate 1.8 mg sodium phosphate dibasic anhydrate 0.7 mg sodium citrate 5.8 mg sodium chloride 6.8 pg citric acid in WFI, USP... 

To be reconstituted with either 7.2 mL or 1.1 mL of sterile WFI, giving Per 35mg vial 222mg mannitol IV infusion 20.4mg sodium phosphate monobasic monohydrate ... 

To be reconstituted with 1 mL sterile WFI containing 1.0 mg Poloxamer 188 (0.15mg/mL) Per 5mg vial 33.0mg mannitol 3.0mg sodium phosphate monobasic monohydrate 8.8 mg sodium phosphate dibasic heptahydrate Per vial 10.6 mg mannitol IV 15.9mg/mL L-alanine 12.6-14.3 mg of dibasic sodium phosphate... 

Per 1 mL polysorbate solution 0.05mg/mL polysorbate 80 2.12mg/mL sodium phosphate monobasic monohydrate 0.66mg/mL sodium phosphate dibasic anhydrous 8.18mg/mL sodium chloride (pH 6.2 0.2)... 

Per 1 mL 1.36 mg glycine 36.0 mg mannitol 1.04mg sodium phosphate dibasic anhydrous 0.36 mg sodium phosphate monobasic monohydrate... 

Sodium dihydrogen phosphate, monohydrate (Sodium phosphate, monobasic), NaH2P04 H20. Mol. wt. 137.99. Suppliers Baker, Fisher. 

Each milliliter contains 5 mg of Daclizumab and 3.6 mg of sodium phosphate monobasic monohydrate, 11 mg of sodium phosphate dibasic heptahydrate, 4.6 mg of sodium chloride, 0.2 mg of polysorbate 80 and may contain hydrochloric acid or sodium hydroxide to adjust the pH to 6.9. No preservatives are added. 

Two formulations contain excipients as follows polysorbate solution contains 0.05 mg of polysorbate 80, 2.12 mg of sodium phosphate monobasic monohydrate, 0.66 mg of sodium phosphate dibasic anhydrous, and 8.18 mg of sodium chloride in water for injection, LISP (per 1 mL) at pH 6.2 + 0.2. Albumin solution contains 2.5 mg of albumin (human), 2.23 mg of sodium phosphate monobasic monohydrate, 0.53 mg of sodium phosphate dibasic anhydrous, and 8.18 mg of sodium chloride in water for injection, LISP (per 1 mL) at pH 6.0 + 0.3. 

Each vial contains 37 mg of alpha-galactosidase beta as well as 222 mg of mannitol, 20.4 mg of sodium phosphate monobasic monohydrate, and 59.2 mg of sodium phosphate dibasic heptahydrate. Following reconstitution as directed, 35 mg of agalactosidase beta (7 ml) may be extracted from each vial. 

Must be diluted prior to administration in 0.9% sodium chloride injection, USP containing 0.1% of albumin (human). The solution in each vial contains a nominal laronidase concentration of 0.58 mg/mL and a pH of approximately 5.5. The extractable volume of 5.0 ml from each vial provides 2.9 mg of laronidase, 43.9 mg of sodium chloride, 63.5 mg of sodium phosphate monobasic monohydrate,... 

Each vial also contains 1.36 mg of glycine, 36.0 mg of mannitol, 1.04 mg of sodium phosphate dibasic anhydrous, and 0.36 mg of sodium phosphate monobasic monohydrate. 

M Sorenson s phosphate buffer Stock Dissolve 7.176 g sodium phosphate monobasic monohydrate (NaH2P04-H20) in 100 mL distilled H20. Dissolve 49.4 g of sodium phosphate (NaP04) in 750 mL distilled H20. Mix the sodium phosphate monobasic monohydrate and sodium phosphate solutions in a 1 L cylinder. Bring volume to 1 L with distilled water. The pH should be 7.6. Do not adjust pH. This may be stored at room temp for up to 6 months. For use dilute with distilled water to 0.1 M. 

---